ReviewDiscovery medicine2012
Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer.
Review in Discovery medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04697264 (Adipocytokines and Their Relationship to Obesity and Endometrial Cancer), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adipocytokines and Their Relationship to Obesity and Endometrial Cancer
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2019Pooled it
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2015Pooled it
- Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.Journal of the National Cancer Institute · 2016Trial
- Mindfulness-Oriented Recovery Enhancement Restructures Reward Processing and Promotes Interoceptive Awareness in Overweight Cancer Survivors: Mechanistic Results From a Stage 1 Randomized Controlled Trial.Integrative cancer therapiesTrial
- Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer.Fundamental research · 2025Review
- Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.Cancers · 2025Article
- Accelerated midlife endocrine and bioenergetic brain aging in APOE4 females.Frontiers in aging neuroscience · 2025Article
- High BMI-attributable female-specific cancers: a comprehensive analysis of the global disease burden and trends from 1990 to 2021 and projections to 2040.Frontiers in oncology · 2025Article
- Decision-Making About Fertility Preservation After Cancer Diagnosis: A Qualitative Study of Patients' Experiences and Perspectives.Cancer management and research · 2025Article
- Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.Frontiers of medicine · 2024Review
- Review
- Understanding the patient experience in nonsurgical management of endometrial cancer and complex atypical hyperplasia due to obesity: A qualitative analysis.Gynecologic oncology reports · 2024Article
- A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review).Oncology letters · 2024Review
- The Effectiveness of Metabolic Bariatric Surgery in Preventing Gynecologic Cancer - from Pathophysiology to Clinical Outcomes.Journal of Cancer · 2024Review
- Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets.The Journal of steroid biochemistry and molecular biology · 2023Article
- Cross-sectional associations between phthalates, phenols, and parabens with metabolic syndrome risk during early-to-mid adolescence among a cohort of Mexican youth.Environmental research · 2023Article
- Obesity is associated with alterations in antral follicle dynamics in eumenorrheic women.Human reproduction (Oxford, England) · 2023Observational
- Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes.Cancers · 2022Review
- Platelet-rich plasma treatment in patients with refractory thin endometrium and recurrent implantation failure: A comprehensive review.Clinical and experimental reproductive medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The lifetime risk for developing endometrial cancer, the fourth most common malignancy in women, is approximately 3%. Endometrial cancer is a hormone-driven cancer, with approximately 80% of endometrial cancers arising attributable to either an excess of estrogen or a lack of progesterone. In the normal endometrium, the proliferative effects of estrogen are normally countered by progesterone, but the absence of progesterone allows estrogen to induce oncogenesis, an effect that is amplified in situations of excess estrogen. One of the major emerging causes of the estrogen/progesterone imbalance is obesity. Obesity is associated with several hormonal derangements as well as dysregulation of insulin/insulin-like growth factor activity, which collectively contribute to hyperplasia and carcinogenesis in the endometrium. In this article, we provide an in-depth description of how obesity mechanistically promotes this hormone and growth factor imbalance. Given that endometrial cancer is clearly associated with obesity, we put forth the hypothesis that a large portion of these cancers might be prevented by treatment with progesterone.
Indexed as
Identifiers
23021376PMC3964851W1590256786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.